関連する実験動画
Updated: May 2, 2026
06:48
A Reporter Assay to Analyze Intronic microRNA Maturation in Mammalian Cells
Published on: June 16, 2022
1.4K
アルツハイマー病の単細胞トランスクリプトミア分析
Hansruedi Mathys1,2, Jose Davila-Velderrain3,4, Zhuyu Peng1,2
1Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nature
|May 3, 2019
まとめ
この研究では,アルツハイマー病 (AD) の患者の脳細胞を分析し,異なる細胞サブ集団と早期の細胞タイプ特有の変化を明らかにしました. 骨髄形成プロセスは著しく変化し,ADにおけるその役割を強調した.
科学分野:
- 神経科学
- ゲノミクス
- 分子生物学
背景:
- アルツハイマー病 (AD) は複雑な神経変性疾患で,分子メカニズムはよくわかっていません.
- 現存する研究では,AD病理の細胞型特異的な解像度が欠けていることが多い.
研究 の 目的:
- 単核トランスクリプトミクスを用いてアルツハイマー病の分子と細胞の異質性を調査する.
- 疾患の進行過程において,AD病理によって最も影響を受ける細胞タイプと経路を特定する.
主な方法:
- 異なるAD病理を持つ48人の前頭前皮質から 80,660個の単核トランスクリプトームを分析した.
- 6つの主要な脳細胞の細胞群の識別と特徴付け.
主要な成果:
- 骨髄形成,炎症,ニューロン生存レギュレータを含むADに関連した細胞タイプ特有のサブ集団を発見した.
- 病気の進行における早期の特異的な転写変化を観察し,全局的なストレス反応に関連する後期的な遺伝子を観察した.
- 性別別特有の転写的差異と,病気に関連したサブ集団における女性細胞の過剰表現を特定した.
結論:
- 骨髄形成プロセスは,複数の細胞タイプで繰り返し混乱し,アルツハイマー病の病理生理学における重要な役割を示唆しています.
- この研究は,ADの分子基盤を理解するための貴重な単細胞のトランスクリプトミックのリソースを提供します.
- 細胞反応の性差はADの病原性を理解する上で極めて重要です.
さらに関連する動画
関連する概念動画
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35